Shares of Cerebras Systems rocketed 15.3% to $231.81 Monday after a rare Wall Street stampede: all nine analysts initiating coverage came out bullish, with price targets ranging from $250 to $340 . The move is striking for a company that IPO'd barely three weeks ago at $185 and has already whipsawed between $386 and $197. For investors, the question is whether the hype matches the math.
Wall Street's Bet Rests on One Giant Chip — Literally
Cerebras is the only supplier of wafer-scale processors, which have orders of magnitude more on-chip memory and bandwidth than any other AI chip . Wedbush argues the company's public debut coincides with AI's shift from training to inference — the stage where speed, not raw computing power, determines commercial value . That timing matters: Mizuho estimates the "fast inference" market alone will grow at a 291% compound rate to roughly $550 billion by 2030 . Being the sole maker of a chip purpose-built for that segment gives Cerebras a pricing edge — for now.
A $20 Billion OpenAI Contract Anchors the Revenue Story
In January 2026, Cerebras announced a $20 billion-plus compute deal with OpenAI, deploying approximately 750 megawatts of capacity through 2028, with an option for an additional 1.25 gigawatts . UBS notes Cerebras is currently the only supplier shipping to OpenAI under a prepaid arrangement . Revenue has already scaled from $25 million in 2022 to $510 million in 2025, with projections hitting $6.8 billion by 2028 . That trajectory is what justifies the otherwise eye-popping valuation.
The Price Tag Still Demands a Leap of Faith
Cerebras trades at a price-to-earnings ratio of roughly 225, despite achieving 76% revenue growth over the last twelve months . The consensus $300 target is derived from a 10x enterprise-value-to-sales ratio applied to projected 2029 revenue of $11 billion — revenue the company hasn't come close to generating yet. InvestingPro analysis suggests the stock is overvalued relative to its fair-value estimate . If OpenAI's option isn't exercised or Amazon's collaboration stalls, those projections unravel fast.
Customer Concentration Is the Elephant in the Room
Needham itself acknowledges that meaningful upside depends on whether OpenAI exercises its additional capacity option or Amazon takes delivery of significant Cerebras systems . A company deriving most of its forward revenue from two customers carries execution risk that no analyst rating can eliminate. The bull case is real — but so is the fragility.